TELA Bio TELA 深 滬
等待開盤 02-07 09:30:00 美东时间
0.8108
+0.011
+1.35%
華盛通- 最 高0.8385
- 今 開0.80
- 成交量 31.91万股
- 最 低 0.72
- 昨 收 0.80
- 總市值 3610.54万
- 52周最高 2.96
- 市盈率 靜 --
- 換手率 0.72%
- 52周最低 0.6759
- 委 比 -60.00%
- 總股本 4453.05万
- 歷史最高 23.545
- 量 比 0.29
- 振 幅 14.81%
- 歷史最低 0.6759
- 每 手 1
- 風險率 0.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多TELA Bio Grants Restricted Stock Units to New Employees
TELA Bio Grants Restricted Stock Units to New Employees TELA Bio Inc. has announced that its Compensation Committee has approved inducement grants of restricted stock units covering 14,250 shares of common stock to five newly hired employees. These restricted stock units will vest in equal annual in
01-26 15:26
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TELA Bio, Inc. announced inducement grants of 14,250 restricted stock units to five new employees, vesting over four years. The company focuses on innovative soft-tissue reconstruction solutions, leveraging patients' natural healing responses to minimize synthetic material use. Forward-looking statements are included, and investors are advised to review risks disclosed in SEC filings.
01-23 21:05
Small Medtech TELA Bio Takes On Becton Dickinson, Alleges Hernia Mesh Monopoly
TELA Bio is suing Becton Dickinson for allegedly abusing its monopoly power in the hernia mesh market to limit competition and harm patients.
2025-12-23 21:48
Becton, Dickinson accused of hindering competition in hernia mesh market
Tela Bio (TELA) has filed a lawsuit accusing Becton, Dickinson (BDX) of stymying competition in the US market for surgical hernia mesh. The lawsuit, filed on Dec. 19 in a Philadelphia federal court, c...
2025-12-23 06:54
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TELA Bio, Inc. announces inducement grants of 3,600 restricted stock units (RSUs) to three newly-hired employees. The RSUs, granted on December 9, 2025, vest annually over four years and were awarded under Nasdaq Rule 5635(c)(4) to induce employment.
2025-12-12 21:05
美股大行评级 | 超配！BETA、BillionToOne获多家机构首予评级；摩根大通上调阿斯麦目标价升至1275美元
今日重点评级关注：RBC Capital：上调Neumora Therapeutics评级至"跑赢大市"，目标价从4美元升至7美元；HC Wainwright & Co.：维持ProMIS Neurosciences"买入"评级，目标价从4美元升至18美元
2025-12-02 09:50
Lake Street Maintains Buy on TELA Bio, Lowers Price Target to $3
Lake Street analyst Frank Takkinen maintains TELA Bio (NASDAQ:TELA) with a Buy and lowers the price target from $6 to $3.
2025-12-02 01:03
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
2025-11-19 11:01
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TELA Bio授予17名新员工30,200股限制性股票单位及一名员工25,000股期权，授予日为2025年11月10日。此激励基于纳斯达克规则，作为就业补偿的一部分。期权行使价为$1.19，有效期10年，第一年25% vest，剩余36个月每月 vest。限制性股票单位四年内年度 vesting。
2025-11-17 21:05
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
2025-11-17 10:49
